Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. TLTFF


Primary Symbol: V.TLT

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Releases 2024 Annual Financial Statements

Newsfile 3 days ago

Theralase(R) Closes Non-Brokered Private Placement

Newsfile 3 days ago

Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Newsfile 5 days ago

Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Newsfile February 25, 2025

CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes

ACCESS Newswire February 13, 2025

Theralase(R) Demonstrates Effective Treatment of Herpes

ACCESS Newswire February 12, 2025

Theralase achieves breakthrough Herpes treatment

Jonathon Brown February 10, 2025

Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

ACCESS Newswire February 10, 2025

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

ACCESS Newswire January 27, 2025

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide

Trevor Abes  December 23, 2024

Theralase(R) Launches Three New Clinical Study Sites in USA

ACCESS Newswire December 9, 2024

Theralase(R) Launches New Clinical Study Site in Canada

ACCESS Newswire December 5, 2024

Theralase(R) Release's 3Q2024 Financial Statements

ACCESS Newswire November 27, 2024

Theralase(R) Closes Non-Brokered Private Placement

ACCESS Newswire November 15, 2024

Theralase(R) Extends Warrants

ACCESS Newswire November 12, 2024

Three Canadian small-caps stocks for a contrarian investment

Trevor Abes  October 11, 2024

Latest data from bladder cancer study to propel future growth

Jocelyn Aspa October 10, 2024

Theralase’s bladder cancer drug under investigation in clinical study

Jonathon Brown October 7, 2024

Theralase(R) Provides Update on Bladder Cancer Clinical Study

ACCESS Newswire October 7, 2024

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

ACCESS Newswire September 24, 2024